- Home
- UWMC vs SVRA Comparison
UWMC vs SVRA Comparison
Compare UWMC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
BUY
Current Price
$6.02
Company Overview
Basic Information| Metric | UWMC | SVRA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | 9100 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | UWMC | SVRA |
|---|---|---|
| Price | $4.45 | $6.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $6.50 | ★ $7.33 |
| AVG Volume (30 Days) | ★ 18.7M | 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.68 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.79 | $1.89 |
| 52 Week High | $7.14 | $7.01 |
Technical Indicators
Market Signals| Indicator | UWMC | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 57.84 |
| Support Level | $4.40 | $5.86 |
| Resistance Level | $4.76 | $6.06 |
| Average True Range (ATR) | 0.26 | 0.36 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 50.97 | 92.46 |
Price Performance
Historical Comparison UWMC
SVRA
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.